CYTORA at The International MSA Congress Boston 2025: Prof. Sandu Pitaru, Co-founder, CSO,  VP R&D & Clin Affairs and Prof. Tanya Gurevich, KOL of MSA, presented interim results of the Phase I clinical study for treating patients with moderate and advanced Multiple System Atrophy (MSA) with hOMSC300.

Prof. Sandu Pitaru, Co-founder, CSO, VP R&D & Clin Affairs and Prof. Tanya Gurevich, KOL of MSA presented the interim results of the Phase I clinical study for treating moderate and advanced Multiple System Atrophy (MSA) as well as preclinical results from a mouse model of MSA at the International MSA Congress in Boston 2025. The safety data collected to date demonstrate that intrathecal administration of hOMSC300, CYTORA’s investigational, allogeneic, off the shelf cell therapy, is safe. In addition, preliminary efficacy data suggest that hOMSC may be efficient as a disease modifying therapy in moderate stages of MSA.